فصلنامه نفس

Dassanayaka S, Jones SP. Recent developments in heart failure. Circulation Research. 2015;117(7):e58-e63.

Ohtani T, Mohammed SF, Yamamoto K, et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. European Heart Journal. 2012;33(14):1742–1749.

Choi H-M, Park M-S, Youn J-C. Update on heart failure management and future directions. Korean Journal of Internal Medicine. 2019;34(1):11–43.

Malik A, Brito D, Vaqar S, et al. Congestive heart failure. [Updated 2022 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430873

Inamdar AA, Inamdar AC. Heart failure: diagnosis, management and utilization. Journal of Clinical Medicine. 2016;5(7):62

Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136(6):e137–161.

Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes, Obesity and Metabolism 2012;14(1):83–90.

Scheen AJ, Lancellotti P. SGLT2 inhibitors, new option to prevent or treat heart failure. Revue Medicale de Liege. 2021 Apr;76(4):248–55 (in French).

Oh J, Lee SH, Lee CJ, Kang SM. Sodium-glucose co-transporter 2 inhibitors: a new path for heart failure treatment. Korean Circulation Journal. 2021;51(5):399–408.

Ahmed HM, Khraishah H, Cho L. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. European Heart Journal. 2018;39(25):2368–2375.

Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133(8):698–705.

Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. American Journal of Medicine. 2017;130(6S):S30–S39.

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. New England Journal of Medicine. 2020;383(15):1413–1424.

McMurray JJ V, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine. 2019;381(21):1995–2008.

Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458–468.

Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142(23):2205–2215.

Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovascular Diabetology. 2019;18(1):129.

Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2016;374(11):1094.

Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Cardiac Failure Review. 2017;3(1):52–55.

Rau M, Thiele K, Hartmann N-UK, et al. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. Cardiovascular Diabetology. 2021;20(1):6.

Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. European Heart Journal. 2016;14;37(19):1526–1534.

Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41(2):356–363.

Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nature Reviews Cardiology. 2011;8(1):30–41.

Täger T, Atar D, Agewall S, et al. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Failure Reviews. 2021;26(6):1421–1435.

Anker SD, Butler J, Filippatos G, et al. Effect of Empagliflozin on cardiovascular and renal outcomes in patients with heart failure by